These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20231672)

  • 1. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
    Killestein J; van der Meer ML; Regelink JC; Huijgens PC; Polman CH
    Neurology; 2010 Mar; 74(11):934; author reply 934. PubMed ID: 20231672
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
    Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
    Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
    Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
    Bernitsas E; Wei W; Mikol DD
    Ann Neurol; 2006 Jan; 59(1):206-9. PubMed ID: 16374818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
    Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
    Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
    Dörr J; Bitsch A; Schmailzl KJ; Chan A; von Ahsen N; Hummel M; Varon R; Lill CM; Vogel HP; Zipp F; Paul F
    Neurology; 2009 Sep; 73(12):991-3. PubMed ID: 19770476
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.
    Novoselac AV; Reddy S; Sanmugarajah J
    Leukemia; 2004 Sep; 18(9):1561-2. PubMed ID: 15215874
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.
    Cattaneo C; Almici C; Borlenghi E; Motta M; Rossi G
    Leukemia; 2003 May; 17(5):985-6. PubMed ID: 12750718
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
    Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
    Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient.
    Tanasescu R; Debouverie M; Pittion S; Anxionnat R; Vespignani H
    J Neurol; 2004 Jun; 251(6):762-3. PubMed ID: 15311359
    [No Abstract]   [Full Text] [Related]  

  • 12. Leukaemia due to mitoxantrone.
    Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia.
    Cartwright MS; Jeffery DR; Lewis ZT; Koty PP; Stewart WT; Molnár I
    Neurology; 2007 May; 68(19):1630-1. PubMed ID: 17485652
    [No Abstract]   [Full Text] [Related]  

  • 14. Mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
    [No Abstract]   [Full Text] [Related]  

  • 15. Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.
    Zecca C; Petrini L; Limoni C; Staedler C; Gobbi C
    Eur Neurol; 2011; 65(1):40-5. PubMed ID: 21196739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.
    Wundes A; Kraft GH; Bowen JD; Gooley TA; Nash RA
    Clin Neurol Neurosurg; 2010 Dec; 112(10):876-82. PubMed ID: 20727669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone-induced extravasation.
    Luke E
    Oncol Nurs Forum; 2005 Jan; 32(1):27-9. PubMed ID: 15682531
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
    Ellis R; Boggild M
    Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mitoxantrone, a new reality].
    Ruiz-Peña JL; Izquierdo G
    Rev Neurol; 2003 Apr 1-15; 36(7):698-9. PubMed ID: 12666055
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
    Ko MW; Tamhankar MA; Volpe NJ; Porter D; McGrath C; Galetta SL
    J Neurol Sci; 2008 Oct; 273(1-2):144-7. PubMed ID: 18687447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.